Phumeza Tisile was treated for MDR-TB in 2010 and suffered severe side effects from the drug, kanamycin. Her experiences drove her to join the global bedaquiline advocacy campaign. After years of work from the campaign, including legal opposition to J&J’s patents, nearly universal access to bedaquiline was achieved in 2023, preventing J&J from extending its monopoly and enabling generic production. Tisile describes her work on the campaign and the challenges they faced along the way to make bedaquiline widely accessible. Read more here.
top of page
Recent Posts
See AllThe results of the TB-CHAMP trial were recently published. They showed that prophylactic levofloxacin can significantly reduce the risk...
190
This month, the Indian Patent Office denied the last of the three Janssen patent extension applications for bedaquiline. While TB...
100
The Institute of Tropical Medicine has announced two initiatives to honor the legacy of Armand Van Deun: a new meeting room in his name...
560
bottom of page
Commentaires